What is vaccine sinovac?

China’s coronavirus Vaccines become an alternative in this pandemic situation. China starts to race other countries to develop vaccines for covid19. Vaccine Sinovac produced by china’s Sinovac Biotech Company, the vaccine that works by using killed virus particles with minimum response of serious disease to human body’s immune. Reported from BBC, CoronaVac is a more traditional vaccine method that is successfully used in many vaccines, like rabies. Said Prof luo dahai (Nanyang Technology University). mRna vaccines are a new type of vaccine and currently does not work successfully in the population. He adds
Vaccine Sinovac is used in some developing countries; it has an advantage than other vaccine. They can keep it in a standard refrigator at 2-8 degrees Celsius than Moderna’s vaccine that needs to be stored at -20C and Pfizer’s vaccine at -70C.
For developing countries, vaccine Sinovac will be more effective. It is useful which might not be able to keep large amount of vaccine in low temperature.

In Indonesia the efficiency level at 65.3%, Turkey at 91.25% and Brazil at 78% (from the final test stage).
From the result in Brazil, Sao Paulo’s Governor, Joao Dario plans to immediately get vaccine approval to be able to run vaccinations starting January25, 2021 and will vaccinate 45 million people in the Brazilian capital. Reported from CNBC Indonesia. With this kind of vaccines, we will find a new hope to end this pandemic situation; even it does not directly stop the spread of Covid-19. It can be an alternative to inhibits spreading of corona virus pandemic.

Under review

China Vaccine and China Pharmaceutical Vaccine are considered as potential vaccine candidates that are affordable and easy to distribute. Unlike Pfizer-Bio NTech and Moderna vaccines, Chinese vaccines do not require expensive cold storage. Sinovac has signed agreements with the governments of at least six countries and plans to provide Brazil with 46 million doses of Sinovac vaccine, 50 million doses to Turkey, and seven countries. 5 million doses to Hong Kong. It will also supply 40 million doses of vaccine to Indonesia, the vaccine concentrate before the vaccine is divided into vials, for local production. According to Reuters, Thailand has already ordered 2 million Sinovac, which is expected to receive the first batch of 200,000 more agents in February, and the Philippines has ordered 25 million, and the first batch of expectations will arrive next month.

However, after the Brazilian trial data is announced, other countries are re-examining potential plans. Singapore Health Minister said that officials will review the Chinese vaccine in the vaccination to their citizens. Singapore has not yet approved the vaccine, but it does have a procurement agreement with the company. According to the “Straits Times”, the Minister of Health, Gan Jinyong, said that the vaccine needs to pass the regulatory procedures and authorization of the Singapore ‘Health Science Administration.

According to Reuters, Malaysia also stated that it will seek more data from Sinovac before approving and purchasing supplies. In Hong Kong, where the agreement was signed with Sinovac, a senior medical consultant said that a team of experts will review each vaccine based on clinical trial data. Although Brazil`s health agency regulator Anvisa voted on Sunday to authorize the emergency use of the Sinovac vaccine, it said it was unable to obtain important data on the vaccines studied in the third phase, such as the protection provided by the vaccine. Duration and its impact on the elderly and other specific groups, such as co-patients.

Different efficacy rates

Part of the confusion over Sinovac’s vaccine has been around different efficacy rates and the data made available.

Turkey, which approved the Sinovac vaccine for emergency use on Wednesday, reported an efficacy of 91.25%, while Indonesia reported 65.3%. Data from Brazil, meanwhile, showed 50.38% efficacy for those who suffered very mild cases of Covid-19. But the rate rose to 78% for mild to severe cases. “It is difficult to interpret all this information without seeing the full datasets. This highlights the problem of issuing data by press release rather than publication in a peer-reviewed journal,” Prof. Lawrence Young, virologist and Professor of Molecular Oncology at the University of Warwick, said in a statement. “It also emphasizes the different approaches to requirements for regulatory approval.”